食品和药物管理局批准Tezspire用于严重鼻腔聚虫、减少外科手术和类固醇。 FDA approves Tezspire for severe nasal polyps, reducing surgery and steroids.

美国FDA批准Tezspire (tezepelumab),一种生物向胸膜层淋巴质蛋白,用于12岁及以上的成年人和青少年的补充维持治疗,这些患者患有不充分控制的鼻多的慢性鼻炎. The U.S. FDA has approved Tezspire (tezepelumab), a biologic targeting thymic stromal lymphopoietin, for add-on maintenance treatment of adults and adolescents aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal polyps. 以第三阶段试验数据为依据的核准表明,症状大有改善,外科手术需求接近消除,以及花生类固醇使用量减少。 The approval, based on phase III trial data, shows significant improvements in symptoms, near-elimination of surgery needs, and reduced corticosteroid use. 这是为这一病症批准的首例创伤后应激综合症定向疗法,已在多个国家获准治疗严重哮喘。 It is the first TSLP-targeting therapy approved for this condition and is already approved for severe asthma in multiple countries.